The Doctor’s Office

DUBLIN--( BUSINESS WIRE )--The "Physician Office In Vitro Diagnostic (IVD) Test Markets" report has been added to ResearchAndMarkets.com's offering. This report analyzes trends in global demand for in vitro diagnostic (IVD) products used in physicians' office laboratories. Specific products consist of reagents, test kits, standards and controls, and instruments and systems based on immunoassay, clinical chemistry, hematology, molecular, microbiology, and coagulation technologies. Physicians' office laboratories are defined as point-of-care (POC) testing sites within traditional practices or urgent care centers staffed by one or more physicians. Most of these laboratories implement IVD procedures through one or more portable desktop instruments that yield rapid diagnostic results. Information and data appearing in this report include: Macroeconomic, demographic, epidemiological, and healthcare indicators that influence product demand patterns and growth opportunities Projected global product demand by type and technology for the years 2022 through 2027 The projected value of regional and selected national markets for physicians' office laboratory IVD products in each of the forecast years (2022 through 2027). The report also includes profiles of the major producers of physicians' office laboratory IVD products. Report coverage extends to worldwide markets, but focuses on the United States and other developed countries. The majority of physicians' practices in the developing world are located in hospitals and outpatient clinics and do not engage actively in patient testing. In addition, the report profiles key companies in the market, including: Abbott Laboratories Abingdon Health ACON Laboratories, Inc. ArcDia International Oy Ltd. Axis-Shield Diagnostics Ltd. Becton Dickinson and Company (BD) binx health, inc. Bio-Rad Laboratories, Inc. Biocartis NV Biomerica, Inc Key Topics Covered: Chapter 1: Introduction Scope & Report Coverage Methodology Sources of Information Chapter 2: Executive Summary Physicians' Office Laboratories: Market Overview Product Demand Patterns Geographical Markets Size and Growth of the Market Chapter 3: Market Environment Overview Global Economic Outlook Gross Domestic Product Per Capita Gross Domestic Product Population Age Distribution Population 50 Years & Older Population 65 Years & Older Global Healthcare Trends Medical Conditions Health Expenditures Hospital Beds Physicians Patient Activity Acute Care Hospital Admissions Surgical Procedures Physicians' Consultations IVD Tests Traditional Physicians' Offices Urgent Care Centers Physicians' Office Laboratories Chapter 4: Physicians' Office Laboratory (Pol) IVD Products Overview IVD Industry Trends IVD Technologies Immunoassays Clinical Chemistry Molecular IVD Technology Microbiology Hematology Coagulation Histology/Cytology Blood Grouping Other IVD Technologies Industry Regulations Point-Of-Care (Poc) Testing Market Physicians' Office Poc Testing: Market Overview Pol Testing Applications Infectious Disease Pol Tests Covid-19 Pol Tests Other Infectious Disease Pol Tests Colon Cancer Pol Tests Glucose Pol Tests Drugs of Abuse Pol Tests Blood Gas & Electrolyte Pol Tests Coagulation Pol Tests Cardiac Marker Pol Tests Hematology Pol Tests Hba1C Pol Tests Cholesterol Pol Tests Pregnancy/Infertility Pol Tests Cancer Marker Pol Tests Urinalysis Pol Tests Other Pol Tests Pol IVD Product Sales by Type Chapter 5: Geographical Markets Overview United States Canada Mexico Germany France United Kingdom Italy Spain Other Western Europe China India Japan South Korea Australia Other Asia/Pacific Central & South America Eastern Europe Africa/Mideast Chapter 6: Company Profiles Abbott Laboratories Abingdon Health Acon Laboratories, Inc. Arcdia International Oy Ltd. Axis-Shield Diagnostics Ltd. Becton Dickinson and Company (Bd) Binx Health, Inc. Bio-Rad Laboratories, Inc. Biocartis Nv Biomerica, Inc. Biomerieux S.A. Boule Diagnostics Ab Cardinal Health, Inc. Carolina Liquid Chemistries Corporation Chembio Diagnostics, Inc. Danaher Corporation Diasorin S.P.A. Diasys Diagnostic Systems GmbH Diazyme Laboratories, Inc. Ekf Diagnostics Holdings plc Exact Sciences Corporation Genedrive plc Horiba Ltd. Immunostics, Inc. Medmira, Inc. Meridian Bioscience, Inc. Orasure Technologies Pts Diagnostics Quantumdx Group Ltd. Quidelortho Corporation Roche Siemens Healthcare GmbH (Siemens Healthineers) Stago Group Sysmex Corporation Thermo Fisher Scientific, Inc. Trinity Biotech plc Werfen For more information about this report visit https://www.researchandmarkets.com/r/uxce56 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Dublin, May 26, 2021 (GLOBE NEWSWIRE) -- The "Global Liquid Biopsy Market by Clinical Application, Therapeutic Application, Biomarker Type, Analysis Platform, Analysis Purpose, Product, Industry Verticals, and Geography - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering. The global market for liquid biopsy is evaluated to register tremendous growth at a CAGR of 18.54% during the considered phase of 2021-2028. With age, the body's immune system tends to deteriorate. Thus, people above 60 years are susceptible to chronic diseases, such as cancer. Over the year, there has been a significant rise in the number of aged people suffering from breast and colorectal cancer. Hence, the high prevalence of cancer among the geriatric population increases the need for liquid biopsy, thereby driving the liquid biopsy market's development. Furthermore, the technological advancements and rising demand for diagnostics centers are opening new avenues for the studied market. However, the dearth of skilled professionals, coupled with the high cost of liquid biopsy tests, hinders the overall market's growth. Regional Outlook The global liquid biopsy market covers the Asia-Pacific, North America, Latin America, Europe, and the Middle East and Africa regions. The Asia-Pacific is estimated to become the fastest evolving region in the liquid biopsy market over the projected phase 2021-2028. The region provides several lucrative opportunities to the studied market to attain the anticipated growth during the given period. Additionally, the high population base in countries such as India and China is estimated to boost the demand for liquid biopsy in the upcoming years. Other than this, the surge in healthcare spending, along with the rise in awareness regarding the use of liquid biopsy, is motivating the expansion of the liquid biopsy market within the APAC region. Competitive Outlook The renowned companies thriving in the liquid biopsy market are Menarini-Silicon Biosystems, Qiagen NV, Biocept Inc, Illumina Inc, Myriad Genetics Inc, Bio-Rad Laboratories Inc, Guardant Health Inc, Foundation Medicine, Personal Genome Diagnostics, Agilent Technologies Inc, Thermo Fisher Scientific Inc, Adaptive Biotechnologies, MDxHealth SA, Grail, Becton Dickinson and Company (BD), Angle Plc, F Hoffmann-La Roche, and Natera. Agilent Technologies Inc provides instruments, software, services, and consumable solutions to analyze, detect, and quantify the biological and physical properties of substances and products. The company offers its products and services to several sectors, including chemical, environmental, forensics, clinical, and diagnostics. Founded in 1999, it markets its products via direct sales, resellers, distributors, and representatives. Agilent has manufacturing facilities, along with R&D centers globally, with headquarters located in California, the United States. Key Topics Covered: 1. Global Liquid Biopsy Market - Summary 2. Industry Outlook2.1. Impact of COVID-19 on Liquid Biopsy Market2.2. Key Insights2.3. Porter's Five Forces Model2.3.1. Threat of New Entrants2.3.2. Threat of Substitute Products2.3.3. Bargaining Power of Buyers2.3.4. Bargaining Power of Suppliers2.3.5. Competitive Rivalry2.4. Initiatives Pertaining to Liquid Biopsy2.5. Legal, Policy, & Regulatory Framework2.6. Market Attractiveness Index2.7. Vendor Scorecard2.8. Key Market Strategies2.8.1. Contracts and Partnership2.8.2. Business Expansion, Announcements, and Divestitures2.8.3. Acquisitions & Mergers2.8.4. New Product Launches2.9. Market Drivers2.9.1. High Prevalence of Cancer in Geriatric Population2.9.2. Growing Importance of Liquid Biopsy Testing2.9.3. Rising Government Initiatives2.10. Market Restraints2.10.1. Lack of Reimbursement for Liquid Biopsy2.10.2. Disadvantages Associated with Compensation2.10.3. Unavailability of Skilled Professionals2.10.4. High Cost of Liquid Biopsy Test2.11. Market Opportunities2.11.1. Advancement in Technologies2.11.2. Untapped Diagnostic Testing Opportunities in Developing Countries2.11.3. Growing Demand for Diagnostic Centers 3. Global Liquid Biopsy Market - by Clinical Application3.1. Treatment Monitoring3.2. Prognosis and Reoccurrence Monitoring3.3. Treatment Selection3.4. Diagnosis and Screening 4. Global Liquid Biopsy Market - by Therapeutic Application4.1. Lung Cancer4.2. Breast Cancer4.3. Prostate Cancer4.4. Colorectal Cancer4.5. Melanoma Cancer4.6. Other Types of Cancer4.7. Non-Oncology Application 5. Global Liquid Biopsy Market - by Biomarker Type5.1. Nucleic Acid5.2. Protein5.3. Extracellular Vesicles5.4. Cells 6. Global Liquid Biopsy Market - by Analysis Platform6.1. NGS6.2. Microarray6.3. PCR6.4. Proteomics6.5. Other Analysis Platforms 7. Global Liquid Biopsy Market - by Analysis Purpose7.1. Early Detection/Screening7.2. Therapy Guidance7.3. Monitoring7.4. Diagnosis 8. Global Liquid Biopsy Market - by Product8.1. Circulating Tumor DNA (CTDNA)8.2. Circulating Tumor Cells (CTCS)8.3. Cell-Free DNA (CFDNA)8.4. Extracellular Vesicles and Others 9. Global Liquid Biopsy Market - by Industry Verticals9.1. Physicians' Office Laboratories9.2. Hospitals9.3. Clinical Diagnostic Laboratories 10. Global Liquid Biopsy Market - Regional Outlook 11. Competitive Landscape11.1. Adaptive Biotechnologies11.2. Agilent Technologies Inc.11.3. Angle plc11.4. Becton Dickinson and Company (BD)11.5. Biocept Inc.11.6. Bio-Rad Laboratories Inc.11.7. F Hoffmann-La Roche11.8. Foundation Medicine11.9. Grail11.10. Guardant Health Inc.11.11. Illumina Inc.11.12. MDxHealth SA11.13. Menarini-Silicon Biosystems11.14. Myriad Genetics Inc.11.15. Natera11.16. Personal Genome Diagnostics11.17. Qiagen N.V.11.18. Thermo Fisher Scientific Inc. 12. Research Methodology & Scope For more information about this report visit